title: Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
authors.affiliation: Centre d'investigation Clinique CIC 1408, CHU Saint Etienne, France. Electronic address: emilie.chalayer@chu-st-etienne.fr.
authors.forename: E
authors.initials: E
authors.lastname: Chalayer
authors.affiliation: INSERM U1059, Equipe DVH, Université J Monnet, Saint Etienne, France.
authors.forename: C
authors.initials: C
authors.lastname: Chapelle
authors.affiliation: Service d'Hématologie clinique, CHU de Poitiers, France.
authors.forename: X
authors.initials: X
authors.lastname: Leleu
authors.affiliation: Hôpital Tenon, APHP, France.
authors.forename: I
authors.initials: I
authors.lastname: Elalamy
authors.affiliation: INSERM U1059, Equipe DVH, Université J Monnet, Saint Etienne, France.
authors.forename: S
authors.initials: S
authors.lastname: Laporte
authors.affiliation: Centre d'investigation Clinique CIC 1408, CHU Saint Etienne, France.
authors.forename: B
authors.initials: B
authors.lastname: Tardy
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K; D013792:Thalidomide; D000077269:Lenalidomide; D001241:Aspirin